Autologous Bone Marrow Derived MSCs

Generic Name: Autologous Bone Marrow Derived MSCs

Clinical Trials

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

Phase 1

Recruiting

Conditions: AIDS

Interventions: Drug: mesenchymal stem cell
Other: saline

First Posted Date: 2023-07-11

Last Posted Date: 2024-01-11

Lead Sponsor: Cell Energy Life Sciences Group Co. LTD

Target Recruit Count: 150

Registration Number: NCT05939167

Locations: 🇨🇳
Beijing 302 Hospital, Beijing, China
🇨🇳
Shenzhen Third People's Hospital, Shenzhen, China
🇨🇳
Beijing YouAn Hospital, Beijing, China

and more 1 locations

Mesenchymal Stromal Cells for the Treatment of Patients with COVID-19.

Phase 1

Withdrawn

Conditions: COVID-19 Pneumonia
COVID-19

Interventions: Other: Placebo
Biological: Mesenchymal stem cell

First Posted Date: 2022-06-27

Last Posted Date: 2025-02-10

Lead Sponsor: Paulo Brofman

Registration Number: NCT05433298

Locations: 🇧🇷
Paulo Roberto Slud Brofman, Curitiba, Paraná, Brazil

The Safety and Tolerability of Initial Periodontal Therapy Combined With Human Dental Pulp Stem Cell Injection in the Treatment of Chronic Periodontitis

Phase 1

Active, not recruiting

Conditions: Periodontitis

Interventions: Other: Saline solution
Drug: Human Dental Pulp Stem Cells

First Posted Date: 2021-07-30

Last Posted Date: 2023-05-31

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 36

Registration Number: NCT04983225

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijng, China

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

Phase 1

Recruiting

Conditions: COVID-19 Infection
COVID-19-Associated Acute Respiratory Distress Syndrome
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions: Other: Best Practice
Biological: Mesenchymal Stem Cell

First Posted Date: 2020-09-25

Last Posted Date: 2025-03-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT04565665

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection

Phase 1

Completed

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2

Interventions: Biological: Mesenchymal stem cell

First Posted Date: 2020-08-21

Last Posted Date: 2024-12-09

Lead Sponsor: Rohto Pharmaceutical Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT04522986

Locations: 🇯🇵
Osaka University Hospital, Suita, Osaka, Japan

Evaluation of Clinical and Bone Density Improvement After Implantation of Allogenic Mesenchymal Stem Cell From Umbilical Cord on Osteoporosis Patients

Phase 2

Conditions: Osteoporosis

Interventions: Drug: Mesenchymal Stem Cell

First Posted Date: 2020-08-06

Last Posted Date: 2020-08-07

Lead Sponsor: Ahmad Jabir Rahyussalim

Target Recruit Count: 5

Registration Number: NCT04501354

Locations: 🇮🇩
Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia

An Follow-Up Study of Liver Cirrhosis

Completed

Conditions: Decompensated Liver Cirrhosis

First Posted Date: 2018-03-21

Last Posted Date: 2023-11-18

Lead Sponsor: Rohto Pharmaceutical Co., Ltd.

Target Recruit Count: 19

Registration Number: NCT03472742

Locations: 🇯🇵
Niigata University Medical & Dental Hospital, Niigata, Japan

Mesenchymal Stemcells for Radiation Induced Xerostomia

Phase 2

Completed

Conditions: Xerostomia

Interventions: Drug: Mesenchymal stem cell
Drug: Isotonic NaCl

First Posted Date: 2015-07-31

Last Posted Date: 2022-12-28

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 30

Registration Number: NCT02513238

Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction

Phase 1

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: mesenchymal stem cell

First Posted Date: 2015-01-26

Last Posted Date: 2019-01-09

Lead Sponsor: Pharmicell Co., Ltd.

Target Recruit Count: 10

Registration Number: NCT02344849

Locations: 🇰🇷
Asan medical center, Seoul, Korea, Republic of

Hypoxia and Inflammatory Injury in Human Renovascular Hypertension

Phase 1

Completed

Conditions: Renal Artery Stenosis
Ischemic Nephropathy
Renovascular Disease
Chronic Kidney Disease

Interventions: Drug: Mesenchymal stem cell
Procedure: Mesenchymal stem cell delivery with stent placement

First Posted Date: 2014-10-17

Last Posted Date: 2021-01-27

Lead Sponsor: Mayo Clinic

Target Recruit Count: 42

Registration Number: NCT02266394

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Mississippi, Jackson, Mississippi, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy